Somewhat Favorable Media Coverage Somewhat Unlikely to Impact MannKind Corporation (MNKD) Stock Price

News coverage about MannKind Corporation (NASDAQ:MNKD) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MannKind Corporation earned a news impact score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.5885075309613 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Here are some of the media stories that may have effected Accern’s rankings:

A number of brokerages have weighed in on MNKD. Zacks Investment Research lowered MannKind Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. ValuEngine lowered MannKind Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. J P Morgan Chase & Co reissued an “underweight” rating on shares of MannKind Corporation in a research report on Monday, May 22nd. Finally, Maxim Group reissued a “buy” rating on shares of MannKind Corporation in a research report on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the company. MannKind Corporation presently has an average rating of “Hold” and a consensus target price of $0.92.

MannKind Corporation (MNKD) opened at 2.23 on Wednesday. MannKind Corporation has a 12 month low of $0.67 and a 12 month high of $4.35. The stock has a market cap of $233.44 million, a price-to-earnings ratio of 1.68 and a beta of 3.16. The firm has a 50-day moving average price of $1.48 and a 200-day moving average price of $1.48.

MannKind Corporation (NASDAQ:MNKD) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). MannKind Corporation had a net margin of 71.60% and a negative return on equity of 24.93%. The business had revenue of $2.16 million during the quarter, compared to analysts’ expectations of $2.75 million. During the same quarter last year, the business posted $0.08 earnings per share. Equities research analysts expect that MannKind Corporation will post ($0.94) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact MannKind Corporation (MNKD) Stock Price” was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2017/09/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-mannkind-corporation-mnkd-stock-price.html.

MannKind Corporation Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind Corporation (NASDAQ:MNKD)

Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply